Drug Chatter -- Tracking biopharma stock chatter

DrugPatentWatch - Biopharmaceutical Business Intelligence

Profile for Dicerna Pharmaceuticals, Inc. (DRNA)

« Back to company index

DRNA Chatter Timeline

Stock Ticker for DRNA

Most Active Tweeters for DRNA

UserTweets
@AmericanBanking 6
@portefeuillefun 4
@WatchlistN 3
@OlympiaReport 2
@ConsumerFeed 2

Recent Tweets for DRNA

BioBoyScout @BioBoyScout
@RNAiAnalyst 2/5 $DRNA's GalXC™ exact strategy for addressing off-target effects (OTE) is unknown, except for "Exqu… https://t.co/pcvUxOsKlR
May 22nd 2019, 8:05am
AmericanBanking @AmericanBanking
Dicerna Pharmaceuticals Inc Forecasted to Earn Q2 2019 Earnings of -$0.34 Per Share $DRNA https://t.co/OMgTonvFy2 #stocks
May 22nd 2019, 7:05am
TranscriptDaily @TranscriptDaily
Dicerna Pharmaceuticals Inc Forecasted to Earn Q2 2019 Earnings of -$0.34 Per Share $DRNA https://t.co/V6hEQ40S9m
May 22nd 2019, 7:05am
dailypoliticaln @dailypoliticaln
Dicerna Pharmaceuticals Inc $DRNA Expected to Announce Earnings of -$0.31 Per Share https://t.co/juiUhaBeit
May 22nd 2019, 3:05am
dailypoliticaln @dailypoliticaln
Dicerna Pharmaceuticals Inc Expected to Earn Q2 2019 Earnings of -$0.35 Per Share $DRNA https://t.co/5BqACeXnax
May 22nd 2019, 1:05am
ConsumerFeed @ConsumerFeed
Q2 2019 Earnings Estimate for Dicerna Pharmaceuticals Inc $DRNA Issued By SunTrust Banks https://t.co/TpxabXj6FV
May 21st 2019, 1:05am
HCWCO @HCWCO
In today’s Morning Summary, $DRNA announced the dosing of the first patient in its Phase 1 trial of treatment for… https://t.co/VWtWfn0g23
May 20th 2019, 10:05am
ConsumerFeed @ConsumerFeed
Dicerna Pharmaceuticals $DRNA PT Lowered to $20.00 https://t.co/5C3Baq3Zj0
May 20th 2019, 6:05am
AmericanBanking @AmericanBanking
Analysts Set Expectations for Dicerna Pharmaceuticals Inc’s Q2 2019 Earnings $DRNA https://t.co/YnyT9knCxL #stocks
May 20th 2019, 1:05am
AmericanBanking @AmericanBanking
Dicerna Pharmaceuticals Inc $DRNA Expected to Post Earnings of -$0.31 Per Share https://t.co/nZzcfI8Ii8 #stocks
May 19th 2019, 6:05pm
1MinuteStock @1MinuteStock
Wondering about risks of $DRNA? The 21-day volatility is 14.21% https://t.co/y8VUq53r04
May 19th 2019, 2:05pm
WeekHerald @WeekHerald
Dicerna Pharmaceuticals $DRNA Downgraded by Zacks Investment Research to Sell https://t.co/7raO0L5Sgr
May 19th 2019, 9:05am
OlympiaReport @OlympiaReport
Dicerna Pharmaceuticals $DRNA Downgraded by Zacks Investment Research to Sell https://t.co/3nVYSkbsL2
May 19th 2019, 9:05am
ThisLincolnian @ThisLincolnian
Dicerna Pharmaceuticals $DRNA Downgraded by Zacks Investment Research to Sell https://t.co/pIb797jEc7
May 19th 2019, 9:05am
SwingTradeBot @SwingTradeBot
Recent $DRNA technical alerts: Non-ADX 1,2,3,4 Bearish plus 10 more alerts... https://t.co/SvLQTafHg8
May 19th 2019, 9:05am
WKRBNews @WKRBNews
Dicerna Pharmaceuticals $DRNA Stock Rating Lowered by Zacks Investment Research https://t.co/YGW276pYwf #markets
May 18th 2019, 11:05am
macondailynews @macondailynews
SunTrust Banks Lowers Dicerna Pharmaceuticals $DRNA Price Target to $20.00 https://t.co/9F35LhJObT
May 18th 2019, 8:05am
mikegoodma @mikegoodma
$DRNA’ s 3 deals call for it to discover & develop preclinical candidates. The deal w Boehringer against hepatic ta… https://t.co/3tiNdai7JL
May 17th 2019, 2:05pm
TheMarketsDaily @TheMarketsDaily
Dicerna Pharmaceuticals $DRNA PT Lowered to $20.00 https://t.co/iqjh1clPdf
May 17th 2019, 1:05pm
WatchlistN @WatchlistN
Dicerna Pharmaceuticals $DRNA Downgraded by Zacks Investment Research https://t.co/Bzb0Er2RO7
May 17th 2019, 8:05am
AmericanBanking @AmericanBanking
Dicerna Pharmaceuticals $DRNA PT Lowered to $20.00 at SunTrust Banks https://t.co/4gcQQM9jdV #stocks
May 16th 2019, 5:05pm
WatchlistN @WatchlistN
SunTrust Banks Lowers Dicerna Pharmaceuticals $DRNA Price Target to $20.00 https://t.co/JBDsaIXgr8
May 16th 2019, 5:05pm
TranscriptDaily @TranscriptDaily
Dicerna Pharmaceuticals $DRNA Cut to Sell at Zacks Investment Research https://t.co/7NfPKGN4au
May 16th 2019, 1:05pm
ToothFrank @ToothFrank
$DRNA $DRNA Dicerna Pharmaceuticalssaid pre-market Thursday that it has dosed the first patient in its Phase 1 clin… https://t.co/wUM575YKUL
May 16th 2019, 9:05am
RNAiAnalyst @RNAiAnalyst
@BuffSoldierTwo depends on price; still some time to Q4 read-out. $DRNA
May 16th 2019, 8:05am
BuffSoldierTwo @BuffSoldierTwo
@RNAiAnalyst $DRNA Dirk, how soon till this gets partnered. Will you be buying ahead of that?
May 16th 2019, 8:05am
NewsToDesk @NewsToDesk
$DRNA: Dicerna begins patient dosing in early-stage HBV study: https://t.co/7OY3q4dMju
May 16th 2019, 8:05am
MarketCurrents @MarketCurrents
$DRNA - Dicerna begins patient dosing in early-stage HBV study https://t.co/CvlMiQFMM9
May 16th 2019, 7:05am
NewsToDesk @NewsToDesk
$DRNA: Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial …: https://t.co/YsasdjTLC1
May 16th 2019, 7:05am
TheMarketsDaily @TheMarketsDaily
Dicerna Pharmaceuticals $DRNA Downgraded by Zacks Investment Research to “Sell” https://t.co/4aYNQ0xkoK
May 15th 2019, 9:05pm
portefeuillefun @portefeuillefun
Sold 1k $DRNA at $11.46, now 1.5k #vssporte shares.
May 14th 2019, 10:05am
OlympiaReport @OlympiaReport
Comparing Dicerna Pharmaceuticals $DRNA and Cotinga Pharmaceuticals $COTQF https://t.co/aOQSl7lstJ
May 14th 2019, 2:05am
DataTrials @DataTrials
$DRNA Phase 1 Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria… Estimated… https://t.co/pc5CK2qvjU
May 13th 2019, 4:05pm
mikegoodma @mikegoodma
In 1Q call, Fambrough clarifies $DRNA approach to HBV. In a multi-pronged approach, RNAi is uniquely suited to redu… https://t.co/5SVqn0y9uR
May 13th 2019, 2:05pm
portefeuillefun @portefeuillefun
Bought 1.5k $DRNA at $11.00, now 2.5k #vssporte shares.
May 13th 2019, 9:05am
portefeuillefun @portefeuillefun
Buy 1.5k $DRNA, limit $11.50, GTC. #vssporte
May 13th 2019, 6:05am
intercooleronli @intercooleronli
Dicerna Pharmaceuticals $DRNA Shares Down 6.2% on Disappointing Earnings https://t.co/XI74AUmHMe #investingnews
May 12th 2019, 1:05am
ledgerzette @ledgerzette
Dicerna Pharmaceuticals $DRNA Shares Down 6.2% on Disappointing Earnings https://t.co/tTNMfvDAIS #stocks
May 12th 2019, 1:05am
bulletin_en @bulletin_en
Comparing of Coherus BioSciences Inc. $DRNA https://t.co/W5q0ukFpdk
May 11th 2019, 6:05pm
RNAiAnalyst @RNAiAnalyst
$DRNA, in their frenzy to catch up w/ $ALNY on PH, playing a wild PK/PD guessing game. After single dose phase I/II… https://t.co/kExgC6U8Bm
May 11th 2019, 4:05pm
dakotafinancial @dakotafinancial
Dicerna Pharmaceuticals $DRNA Issues Earnings Results https://t.co/tIKNeECvfI
May 11th 2019, 11:05am
WatchlistN @WatchlistN
Dicerna Pharmaceuticals $DRNA Announces Quarterly Earnings Results, Misses Expectations By $0.16 EPS https://t.co/aULgYNbAYE
May 11th 2019, 11:05am
AmericanBanking @AmericanBanking
Financial Survey: Cotinga Pharmaceuticals $COTQF versus Dicerna Pharmaceuticals $DRNA https://t.co/LtTlTEmFVX #stocks
May 11th 2019, 7:05am
bbnsnews @bbnsnews
Dicerna Pharmaceuticals $DRNA Issues Earnings Results https://t.co/AdjELY0hqL
May 11th 2019, 12:05am
AmericanBanking @AmericanBanking
Dicerna Pharmaceuticals $DRNA Releases Earnings Results, Misses Estimates By $0.16 EPS https://t.co/JCnhcA3dSu #stocks
May 11th 2019, 12:05am
derekavinay @derekavinay
RT @mikegoodma: 2H data I'm looking forward to: $DRNA P1 in HBV; $MGEN P2 in keloids & MRG-110 (partnered w Servier) with P1s in heart fail…
May 10th 2019, 7:05pm
StockTexts @StockTexts
$DRNA Dicerna Pharmaceuticals, Inc. SEC Filing: Form 10-Q https://t.co/emgkTfa8BV
May 10th 2019, 3:05pm
portefeuillefun @portefeuillefun
RT @mikegoodma: $DRNA 1Q19 call. PHYOX2, a pivotal trial in 36 pts w PH1 & PH2, will begin dosing w a fixed monthly dose in 2Q19. Fambrough…
May 10th 2019, 10:05am
ProVesting @ProVesting
$DRNA: Dicerna Pharmaceuticals, Inc. (DRNA) CEO Douglas Fambrough on …: https://t.co/sHBHqbMKxT
May 9th 2019, 11:05pm
SiteFocusHQ @SiteFocusHQ
$DRNA Qualitative Analysis of recent earnings identified Dicerna Pharmaceuticals, Inc (NASDAQ: DRNA ) business focu… https://t.co/BbPqyZR9C8
May 9th 2019, 11:05pm

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2019. All rights reserved.